Lumoxiti

Chemical Namemoxetumomab pasudotox-tdfk
Dosage FormInjection (intravenous; 0.04 mg/kg)
Drug ClassMiscellaneous antineoplastics
SystemBlood
CompanyAstraZeneca
Approval Year2018

Indication

  • To treat relapsed or refractory hairy cell leukemia in adults who have received at least two prior systemic therapies. These therapies can include treatment with a purine nucleoside analog.
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Lumoxiti (Moxetumomab Pasudotox-tdfk) Prescribing Information2018AstraZeneca Pharmaceuticals LP, Wilmington, DE
Document TitleYearSource
Moxetumomab pasudotox for advanced hairy cell leukemia.2020MedImmune LLC